215 related articles for article (PubMed ID: 20650309)
1. In vitro and in vivo study of thymosin alpha1 biodegradable in situ forming poly(lactide-co-glycolide) implants.
Liu Q; Zhang H; Zhou G; Xie S; Zou H; Yu Y; Li G; Sun D; Zhang G; Lu Y; Zhong Y
Int J Pharm; 2010 Sep; 397(1-2):122-9. PubMed ID: 20650309
[TBL] [Abstract][Full Text] [Related]
2. [Preparation and properties of Talpha1 loaded injectable sustained release microspheres].
Zhu Y; Lu Y; Zhong YQ
Yao Xue Xue Bao; 2007 Feb; 42(2):211-5. PubMed ID: 17518054
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of poly (ϵ-caprolactone-co-DL-lactide) as a biodegradable material for in situ forming implants: evaluation of drug release and in vivo degradation.
Zhang X; Zhang C; Zhang W; Meng S; Liu D; Wang P; Guo J; Li J; Guan Y; Yang D
Drug Dev Ind Pharm; 2015 Feb; 41(2):342-52. PubMed ID: 24320881
[TBL] [Abstract][Full Text] [Related]
4. Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres.
Blanco-Príeto MJ; Campanero MA; Besseghir K; Heimgatner F; Gander B
J Control Release; 2004 May; 96(3):437-48. PubMed ID: 15120900
[TBL] [Abstract][Full Text] [Related]
5. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
Kranz H; Bodmeier R
Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
[TBL] [Abstract][Full Text] [Related]
6. On the design of in situ forming biodegradable parenteral depot systems based on insulin loaded dialkylaminoalkyl-amine-poly(vinyl alcohol)-g-poly(lactide-co-glycolide) nanoparticles.
Packhaeuser CB; Kissel T
J Control Release; 2007 Nov; 123(2):131-40. PubMed ID: 17854938
[TBL] [Abstract][Full Text] [Related]
7. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) nanoparticles.
Esmaeili F; Dinarvand R; Ghahremani MH; Ostad SN; Esmaily H; Atyabi F
Anticancer Drugs; 2010 Jan; 21(1):43-52. PubMed ID: 19809300
[TBL] [Abstract][Full Text] [Related]
8. Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism.
Wang L; Wang A; Zhao X; Liu X; Wang D; Sun F; Li Y
Int J Pharm; 2012 May; 427(2):284-92. PubMed ID: 22387369
[TBL] [Abstract][Full Text] [Related]
9. Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems.
Patel RB; Carlson AN; Solorio L; Exner AA
J Biomed Mater Res A; 2010 Aug; 94(2):476-84. PubMed ID: 20186771
[TBL] [Abstract][Full Text] [Related]
10. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems.
Dong WY; Körber M; López Esguerra V; Bodmeier R
J Control Release; 2006 Oct; 115(2):158-67. PubMed ID: 16963145
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization and in vitro cytotoxicity of indomethacin-loaded PLLA/PLGA microparticles using supercritical CO2 technique.
Kang Y; Wu J; Yin G; Huang Z; Yao Y; Liao X; Chen A; Pu X; Liao L
Eur J Pharm Biopharm; 2008 Sep; 70(1):85-97. PubMed ID: 18495445
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.
Wang F; Li B; Fu P; Li Q; Zheng H; Lao X
Int J Pharm; 2018 Aug; 547(1-2):611-620. PubMed ID: 29933059
[TBL] [Abstract][Full Text] [Related]
13. Effect of poly(lactide-co-glycolide) molecular weight on the release of dexamethasone sodium phosphate from microparticles.
Jaraswekin S; Prakongpan S; Bodmeier R
J Microencapsul; 2007 Mar; 24(2):117-28. PubMed ID: 17454423
[TBL] [Abstract][Full Text] [Related]
14. Effect of Polymer Permeability and Solvent Removal Rate on
Zhang X; Yang L; Zhang C; Liu D; Meng S; Zhang W; Meng S
Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31658642
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres.
Feng L; Qi XR; Zhou XJ; Maitani Y; Wang SC; Jiang Y; Nagai T
J Control Release; 2006 May; 112(1):35-42. PubMed ID: 16516999
[TBL] [Abstract][Full Text] [Related]
16. Construction and application of a yeast expression system for thymosin alpha1.
Chen F; Chen XM; Chen Z; Jiang HL; Pan XP; Hu ZR; Liu RH; Chen XM
Biocell; 2005 Dec; 29(3):253-9. PubMed ID: 16524246
[TBL] [Abstract][Full Text] [Related]
17. Reduction in burst release of PLGA microparticles by incorporation into cubic phase-forming systems.
Ahmed AR; Dashevsky A; Bodmeier R
Eur J Pharm Biopharm; 2008 Nov; 70(3):765-9. PubMed ID: 18692569
[TBL] [Abstract][Full Text] [Related]
18. Development of andrographolide loaded PLGA microspheres: optimization, characterization and in vitro-in vivo correlation.
Jiang Y; Wang F; Xu H; Liu H; Meng Q; Liu W
Int J Pharm; 2014 Nov; 475(1-2):475-84. PubMed ID: 25219858
[TBL] [Abstract][Full Text] [Related]
19. A sulfate polysaccharide/TNF-related apoptosis-inducing ligand (TRAIL) complex for the long-term delivery of TRAIL in poly(lactic-co-glycolic acid) (PLGA) microspheres.
Kim H; Jeong D; Kang HE; Lee KC; Na K
J Pharm Pharmacol; 2013 Jan; 65(1):11-21. PubMed ID: 23215683
[TBL] [Abstract][Full Text] [Related]
20. In-vitro, ex-vivo, and in-vivo evaluation of buprenorphine HCl release from an in situ forming gel of PLGA-PEG-PLGA using N‑methyl‑2‑pyrrolidone as solvent.
Kamali H; Khodaverdi E; Hadizadeh F; Mohajeri SA
Mater Sci Eng C Mater Biol Appl; 2019 Mar; 96():561-575. PubMed ID: 30606566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
